Clinical trial NCT06997367: Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)
Official title: A Phase II, Randomized, Double-blind Trial to Assess the Safety and Immunogenicity of MTBVAC (BBV169), With BCG Vaccine as a Comparator in Healthy Adolescent and Adult Populations
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Tuberculosis (TB)
Keywords: MTBVAC
BCG
Tuberculosis
Lead sponsor: Bharat Biotech International Limited
Sponsor class: INDUSTRY
First posted: 2025-05-30
Enrollment: 164
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a double-blind, randomized trial assessing the safety and immunogenicity of the MTBVAC vaccine, with BCG as a comparator. A total of 164 participants aged 12 to 65 will be randomized in a 1:1 ratio to receive a single intradermal dose of either MTBVAC or BCG on Study Day 0. Participants will be split into two cohorts based on QFT-Plus assay results (negative and positive), with each cohort including 82 QFT participants.

Group I (Age: ≥ 18 years): 10 adults per cohort will be enrolled and safety reviewed by the Data and Safety Monitoring Board (DSMB) two weeks post-vaccination before recruiting more adults and participants aged 12 to \<18.

Group II (Age: ≥ 12 to \<18 years): After initial adult recruitment, 10 participants per cohort aged 12 to \<18 will be enrolled, also reviewed by the DSMB. The study aims to ensure that at least 20% of participants in both arms are adolescents.
Primary purpose: PREVENTION

Brief summary: Phase II trial to establish the safety, reactogenicity, and immunogenicity of the MTBVAC with a licensed BCG vaccine as a comparator in both TB naïve (QFT PLUS negative) and TB exposed (QFT PLUS positive) healthy adults and adolescents.

Detailed description: Phase II, double-blind, randomized, safety and immunogenicity trial with BCG vaccine as a comparator in 164 healthy adults and adolescents and with both positive and negative interferon gamma release assay (IGRA) test result.

Objective: To evaluate the immunogenicity of MTBVAC compared to BCG in all participants using PBMC Participants meeting the inclusion and exclusion criteria will be randomized within a study cohort in a 1:1 ratio to receive a single dose of MTBVAC or BCG vaccine administered intradermally. Only HIV-negative participants will be eligible for enrolment. A total of 164 participants aged 12-65 years will be enrolled into one of two cohorts based on their based on the QFT-Plus assay results (QFT negative and QFT positive).

Cohort 1 will include 82 QFT Negative participants Cohort 2 will include 82 QFT Positive participants. Study participants will be randomized in a 1:1 ratio within each cohort to receive MTBVAC (Total N=82, includes 41 QFT negative \& 41 QFT positive participants) or BCG (Total N=82, includes 41 QFT negative \& 41 QFT positive participants) Participants will be followed up for safety and Immunogenicity following vaccination via regular visits.

At least 20% of the participants will be the adolescent population in each cohort in treatment and comparator arms.

Eligibility criteria: Inclusion Criteria:

1. Ability to provide written informed consent and informed Assent from Adolescents
2. Participants of either gender of age between ≥12 to ≤65 years at the time of obtaining informed consent/assent.
3. Good general health as determined by the discretion of the investigator (vital signs, medical history, and physical examination).
4. Expressed interest and Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
5. For a female participant of childbearing potential, planning to avoid pregnancy (use of an effective method of contraception or abstinence) from the time of study enrolment until at least three months after IP administration.
6. Male participants of reproductive potential: Willing to use condoms to ensure effective contraception with the female partner from IP administration until three months.
7. No evidence of active TB disease during screening - As confirmed by normal chest radiograph and no sputum positivity by NAAT test for M. tb
8. A negative urine pregnancy test for female participants of childbearing potential.
9. Only participants who are HIV negative 10. Non-diabetic participants with RBS less than 140 mg/dl and as confirmed by medical history

11. Had BCG vaccination, documented through the presence of scar.

Exclusion Criteria:

1. Any chronic febrile illness with oral temperature \> 100.4°F on the day of randomization.
2. Clinical evidence of pulmonary pathology.
3. History of any form of TB Disease.
4. Prior or present anti-TB treatment
5. Received Tuberculin Skin Test (TST) within three months (90 days) prior to Study Day 0.
6. Clinical Evidence of Active TB
7. Participants with household contacts of patients with active TB disease
8. History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations (any vaccine).
9. History of allergic disease or reactions.
10. History of previous administration of experimental TB vaccines.
11. Use of any investigational or non-registered product (drug or vaccine) in another experimental protocol other than the trial vaccines within 30 days preceding the vaccination, or planned use during the trial period.
12. Any chronic drug therapy is to be continued during the trial period.
13. Chronic administration of immunosuppressors or other immune-modifying drugs.
14. Administration of any immunoglobulins, any immunotherapy, and/or any blood products within the three months preceding the vaccination or planned administrations during the trial period.
15. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
16. Participants who are HIV Positive or on ART.
17. Participants with a medical history of diabetes or those whose RBS levels exceed 140 mg/dL
18. Any condition or history of any acute or chronic illness or medication, which, in the opinion of the Investigator, may interfere with the evaluation of the trial objectives.
19. A family history of congenital or hereditary immunodeficiency
20. History of any neurologic disorders or seizures.
21. History of chronic alcohol consumption and/or drug abuse.
22. Congenital defects in the cardiopulmonary and neurological system
23. Pregnant or lactating female.
24. Females who are planning to become pregnant or planning to discontinue contraceptive precautions during the trial period.
25. Those who have been vaccinated with live attenuated vaccines within 30 days of trial vaccine administration and those who are planning to take live attenuated vaccine within 30 days after trial vaccine administration.
26. Administration of any vaccines that are not live attenuated within 30 days before trial vaccine administration.

Primary outcomes:
measure: To evaluate the immunogenicity of MTBVAC compared to BCG in all participants using PBMC
timeFrame: Day 1 through Day 180
Secondary outcomes:
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- Immediate adverse events
timeFrame: 30 minutes of vaccination
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- Solicited adverse events
timeFrame: Day 1 through Day 14
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- Injection site reactions
timeFrame: Day 1 through Day 90
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- Unsolicited adverse events
timeFrame: Day 1 through Day 360
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- Serious adverse events (SAE s)
timeFrame: Day 1 through Day 360
measure: To evaluate the safety and reactogenicity of MTBVAC compared to BCG- AESI (Adverse Event of Special Interest)
timeFrame: Day 1 through Day 360
Other outcomes:
measure: To evaluate QFT conversion and reversion rates in QFT-negative adults and adolescents
timeFrame: Day 1 through Day 180
measure: Humoral immune response in all participants
timeFrame: Day 1 through Day 180
measure: To assess the immunogenicity of MTBVAC compared to BCG using WBA at one site
timeFrame: Day 1 through Day 180
measure: To assess Antigen-specific CD8 response of MTBVAC compared to BCG
timeFrame: Day 1 through Day 180
measure: To evaluate QFT conversion and reversion rates in QFT-negative adults and adolescents
timeFrame: Day 1 through Day 180
Locations:
city: Delhi
country: India
facility: Guru Teg Bahadur Hospital
city: New Delhi
country: India
facility: AIIMS-Delhi
Study officials:
affiliation: Bharat Biotech International Limited
name: Dr.V.Krishna Mohan, PhD
role: STUDY_DIRECTOR
References: